Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NervGen Pharma (NGENF)
OTHER OTC:NGENF
NervGen Pharma (NGENF) Stock Price & Analysis
42 Followers
NGENF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.16 - $2.99
Previous Close$2.06
Volume37.99K
Average Volume (3M)79.91K
Market Cap
$144.88M
Enterprise Value$136.56M
Total Cash (Recent Filing)C$11.66M
Total Debt (Recent Filing)C$197.19K
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 07, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding69,927,649
10 Day Avg. Volume108,066
30 Day Avg. Volume79,911
Standard Deviation0.21
R-Squared0.15
Alpha0.00575
Financial Highlights & Ratios
Price to Book (P/B)-63.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.53Price Target Upside22.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
NervGen Pharma News
PremiumCompany Announcements
NervGen Pharma Strengthens Board for Clinical Advancements
PremiumCompany Announcements
NervGen Pharma Advances NVG-300 for Neurological Disorders
PremiumCompany Announcements
NervGen Pharma Updates at SCI Investor Symposium
PremiumCompany Announcements
NervGen Pharma Unveils New Stock Options Plan
PremiumCompany Announcements
NervGen Pharma Shareholders Endorse Board and Plans
PremiumCompany Announcements
NervGen Pharma Highlights SCI Treatment AdvancesPremiumCompany Announcements
NervGen Pharma Delays Trial Enrollment, Secures FundingOptions Prices
Currently, No data available
---
Ownership Overview
26.60% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
73.39% Public Companies and
Individual Investors
NGENF FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was $1.16 and its highest was $2.99 in the past 12 months.
What is NervGen Pharma’s market cap?
Currently, no data Available
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Aug 07, 2024 which is in 10 days.
How were NervGen Pharma’s earnings last quarter?
Currently, no data Available
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -$0.07.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 70,180,145 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in NGENF
---
NervGen Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.53 (22.82% Upside)
$2.53 (22.82% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.80%
12-Months-Change
Fundamentals
Return on Equity
-139.67%
Trailing 12-Months
Asset Growth
66.43%
Trailing 12-Months
Company Description
NervGen Pharma
NervGen Pharma Corp is a regenerative medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.
---
NGENF Stock 12 Month Forecast
Average Price Target
$2.53
▲(22.82% Upside)
Technical Analysis
Minerva Neurosciences
―
Cassava Sciences
―
Axonics Modulation Technologies
―
Bristol-Myers Squibb
―
Best Analysts Covering NGENF
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+10.90%
reiterated a buy rating 25 days ago
Copying Justin Keywood's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +10.90% per trade.
---